Replies to post #702 on GTC Biotherapeutics (fka GTCB)

[DewDiligence]

Re: [e-mail] article

Thanks, mblimon, for pointing out the misstatements in the article about Pharming. I was not aware of all of these details, but I did detect an anti-Pharming slant in the article when they mentioned Pharming’s competitors in the HAE arena without noting the mishaps that the competitors have had and are having.

Specifically, Jerini had hoped to find a bona fide big-name partner for its HAE program in the U.S., but they ended up settling for KOSP (which, with all due respect to ‘shears,’ is not exactly a Big Pharma). The other competitor, DYAX/GENZ, has had its HAE program delayed by approximately two years when the FDA insisted on a second phase-3 trial to demonstrate efficacy. Regards, Dew